24/7 Market News Snapshot 31 October, 2024 – Biofrontera Inc. Common Stock (NASDAQ:BFRI)

October 31, 2024

DENVER, Colo., 31 October, 2024 (247marketnews.com) – (NASDAQ:BFRI) are discussed in this article.
In a significant advancement for dermatological treatments, Biofrontera Inc. has announced the impressive results of its Phase 3 study (ALA-BCC-CT013), which evaluated the efficacy of Ameluz® in combination with the BF-RhodoLED® lamp for treating superficial basal cell carcinoma (sBCC). The double-blind, randomized, placebo-controlled trial, which included 187 patients, demonstrated remarkable efficacy with a p-value of less than 0.0001, highlighting the compound’s potential in this therapeutic area.

Ameluz®-photodynamic therapy (PDT) achieved a successful complete clearance rate of 65.5% for preselected BCC lesions when compared to only 4.8% in the placebo group. In addition, complete histological and clinical clearance rates for those treated with Ameluz®-PDT reached 75.9% and 83.4%, contrasting sharply with 19.0% and 21.4% from the placebo group. These findings are consistent with prior European studies, further validating Ameluz®’s effectiveness and bolstering its commercial prospects.

Dr. Hermann Luebbert, CEO and Chairman of Biofrontera, expressed optimism about the results, stating, “These compelling findings underscore our commitment to innovative solutions for skin cancer treatment. We aim to submit our FDA dossier by late Q2 or early Q3 of 2025 after final patient follow-ups conclude in December.” The study also recorded high patient satisfaction, with 64.3% rating their treatment outcomes as very good.

Meanwhile, Biofrontera’s stock has experienced a remarkable surge, climbing to $1.350, a 44.56% increase following the announcement of the trial results. The stock’s trading volume has soared to 2.59 million shares, a clear indication of rising investor interest. This robust market activity, in conjunction with the successful clinical data, highlights a pivotal moment for Biofrontera as it positions itself to address the significant and growing need for effective sBCC treatments, with over 3.6 million diagnoses of skin cancer reported annually in the U.S. Biofrontera is poised to play a critical role in advancing innovative solutions for this prevalent condition.

Related news for (BFRI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.